228 related articles for article (PubMed ID: 18475296)
1. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
Widmer N; Decosterd LA; Leyvraz S; Duchosal MA; Rosselet A; Debiec-Rychter M; Csajka C; Biollaz J; Buclin T
Br J Cancer; 2008 May; 98(10):1633-40. PubMed ID: 18475296
[TBL] [Abstract][Full Text] [Related]
2. The role of imatinib plasma level testing in gastrointestinal stromal tumor.
George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S45-50. PubMed ID: 21140148
[TBL] [Abstract][Full Text] [Related]
3. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
[TBL] [Abstract][Full Text] [Related]
4. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
5. A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
Wolf D; Rumpold H
Drug Saf; 2009; 32(11):1001-15. PubMed ID: 19810774
[TBL] [Abstract][Full Text] [Related]
6. The safety profile of imatinib in CML and GIST: long-term considerations.
Thanopoulou E; Judson I
Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
8. Drug plasma monitoring in CML and GIST: A case-based discussion.
Egorin MJ; Mauro MJ; Trent JC
Clin Adv Hematol Oncol; 2009 Nov; 7(11):S1, S3-11. PubMed ID: 20099379
[TBL] [Abstract][Full Text] [Related]
9. [Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
Turjap M; Juřica J; Demlová R
Klin Onkol; 2015; 28(2):105-11. PubMed ID: 25882020
[TBL] [Abstract][Full Text] [Related]
10. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
13. The development and application of imatinib.
Jones RL; Judson IR
Expert Opin Drug Saf; 2005 Mar; 4(2):183-91. PubMed ID: 15794712
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
Kim KP; Ryu MH; Yoo C; Ryoo BY; Choi DR; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
Cancer Chemother Pharmacol; 2011 Aug; 68(2):285-91. PubMed ID: 20957481
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
16. [STI571: a summary of targeted therapy].
Czyz M; Jakubowska J
Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
[TBL] [Abstract][Full Text] [Related]
17. Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.
Kim DW; Tan EY; Jin Y; Park S; Hayes M; Demirhan E; Schran H; Wang Y
Br J Clin Pharmacol; 2011 Feb; 71(2):199-206. PubMed ID: 21219400
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
Tsutsumi Y; Kanamori H; Yamato H; Ehira N; Miura T; Kawamura T; Obara S; Tanaka J; Asaka M; Imamura M; Masauzi N
Leuk Res; 2004 Oct; 28(10):1117-8. PubMed ID: 15289027
[No Abstract] [Full Text] [Related]
19. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?
von Mehren M; Widmer N
Cancer Treat Rev; 2011 Jun; 37(4):291-9. PubMed ID: 21078547
[TBL] [Abstract][Full Text] [Related]
20. Imatinib plasma levels: correlation with clinical benefit in GIST patients.
Widmer N; Decosterd LA; Csajka C; Montemurro M; Haouala A; Leyvraz S; Buclin T
Br J Cancer; 2010 Mar; 102(7):1198-9. PubMed ID: 20179709
[No Abstract] [Full Text] [Related]
[Next] [New Search]